Countries that rely more on price regulation and public financing might be expected to be less vulnerable to corporate influences in health care. But private equity firms are making inroads in ...

An asymptomatic 17-year-old boy who had emigrated from El Salvador was found to have a pleural effusion on a chest radiograph. A small number of parasite eggs were seen in the pleural fluid.

When her mother asks for medical aid in dying, a neurointensivist and palliative care researcher finds herself torn between her doctorly response and her daughterly one, wavering in her convictions.

Xenotransplantation offers a potential solution to the organ shortage crisis. A 62-year-old hemodialysis-dependent man with long-standing diabetes, advanced vasculopathy, and marked dialysis ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Few procedures have gone through a decade of practice-changing clinical trials as impressive as thrombectomy for stroke. Beginning in 2015 with multiple trials showing a benefit with thrombectomy ...

Endovascular treatment (EVT) of stroke with large-vessel occlusion is known to be safe and effective. The effect of EVT for occlusion of medium or distal vessels is unclear. We randomly assigned ...

Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In a multicenter, prospective ...

Familial HLH is a success story in modern medicine. Initially a disease that was largely unknown and fatal, it is now understood on a molecular level and is curable. Moreover, HLH is an archetype ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...

Supported by the Advanced Research Projects Agency for Health (agreement number, 140D042490001); a grant (R01HL141408) from the National Heart, Lung, and Blood Institute; a grant (R01FD007632 ...

A total of 867 patients underwent randomization: 291 were assigned to receive acalabrutinib–venetoclax, 286 acalabrutinib–venetoclax–obinutuzumab, and 290 chemoimmunotherapy (of whom 143 ...